Several challenges exist in developing effective TCR-based therapies. One major issue is immune evasion by tumors, which can downregulate antigen presentation or alter the tumor microenvironment to suppress T cell activity. Additionally, the specificity of engineered TCRs must be carefully managed to prevent off-target effects and minimize the risk of autoimmunity. Another challenge is the identification of suitable tumor antigens that are not expressed on healthy tissues.
